From January to March 2026, multiple companies invested in and incubated by Viva BioInnovator (VBI) continued to achieve significant progress. Key players, including Iterion Therapeutics, Kainova Therapeutics, Grove Biopharma, QurAlis, GenHouse Bio, ABM Therapeutics, and Full-Life Technologies, reported a series of breakthroughs in pipeline advancement, financing, and strategic collaborations.
· Iterion Therapeutics Announces First Patient Dosed in Clinical Trials of Tegavivint for Both Colorectal Cancer and Relapsed/Refractory Osteosarcoma
HOUSTON, March 25, 2026 — Iterion Therapeutics, a clinical-stage, biopharmaceutical company invested by Viva BioInnovator (VBI), reported that the first patient has been dosed at HonorHealth Research Institute in a phase 1/2 clinical trial (NCT07463599) evaluating tegavivint, a first-in-class, small molecule inhibitor of the Wnt/β-catenin pathway, for the treatment of metastatic colorectal cancer (mCRC). This milestone expands Iterion's clinical development into mCRC, a disease with significant unmet need and limited progress in developing targeted therapies.
Previously, on February 10, 2026, Iterion Therapeutics announced that the first patient has been dosed in a clinical study evaluating tegavivint, in combination with gemcitabine for patients with relapsed or refractory osteosarcoma.
· Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors, and Secures $32M CAD in Series B Financing
Montreal, Canada – Strasbourg, France – Boston, United States: on March 10, 2026, Kainova Therapeutics, invested by Viva BioInnovator (VBI), a key player for breakthrough treatments in immuno-oncology and inflammation, announced positive topline results from its Phase I EPRAD study evaluating DT-9081, a proprietary, oral small molecule EP4 receptor (EP4R) antagonist in patients with advanced, recurrent, and metastatic solid tumors.
Additionally, on February 10, 2026, Kainova Therapeutics announced the successful first close of its Series B financing round totaling $32 million CAD, with participation from investors including Viva BioInnovator (VBI).
· Grove Biopharma Reports Preclinical Study in Nature Communications Demonstrating a Novel Approach to MYC and KRAS Degradation
CHICAGO, February 24, 2026 — Grove Biopharma, invested by Viva BioInnovator (VBI), announced the publication of preclinical results demonstrating targeted degradation of two key oncogenic drivers enabled via its Bionic Biologics platform. The peer-reviewed study, titled “Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS,” was published in Nature Communications. (DOI: 10.1038/s41467-026-68913-3).
· QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS
CAMBRIDGE, Mass., February 23, 2026 — QurAlis, a clinical-stage biotechnology company, invested in and incubated by Viva BioInnovator (VBI), announced interim data from its Proof-of-Concept Phase 1/2 ANQUR clinical trial of QRL-201 in people living with amyotrophic lateral sclerosis (ALS). Results from this study demonstrated QRL-201 had an effect on disease progression in ALS patients; this effect was confirmed by markers of clinical efficacy and changes in a clinically relevant biomarker, along with target engagement.
· GenHouse Bio Accelerates Global Oncology Expansion with Multiple Strategic Milestones
SUZHOU, China, February 13, 2026 — GenHouse Bio, a portfolio company of Viva BioInnovator (VBI), announced global partnership on its MAT2A inhibitor synthetic lethality therapy GH31 with Gilead. Previously, in January 2026, GH31 received IND approvals from both the China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA).
Regarding its capital and strategic growth, GenHouse Bio submitted its listing application to the Stock Exchange of Hong Kong (HKEX) on January 16, moving forward with its Hong Kong IPO. This follows the completion of a Crossover financing round exceeding RMB 300 million on January 13, providing robust support for the company's R&D progress and strategic roadmap.
· ABM Therapeutics Transfers Global Rights of MEK Inhibitor ABM-168 to Mosaica Medicines
Shanghai, China / San Diego, USA – January 15 2026 — ABM Therapeutics, invested in and incubated by Viva BioInnovator (VBI), announced the transfer of global rights of ABM-168, its proprietary MEK1/2 inhibitor, to Mosaica Medicines, a Boston-based biotechnology company. Under the terms of the agreement, ABM Therapeutics has received an upfront payment and is eligible to receive additional milestone payments tied to the successful development and commercialization of ABM-168.
· Full-Life Technologies' Partner SK Biopharmaceuticals Secures FDA IND Approval for Alpha-Emitter Radiopharmaceuticals Drug Candidate Accelerating Global Clinical Development
CHENGDU, China, January 12, 2026 — Full-Life Technologies, a portfolio company of Viva BioInnovator (VBI) and a fully-integrated clinical-stage global radiopharmaceutical company, congratulated its partner SK Biopharmaceuticals on receiving the U.S. Food and Drug Administration (FDA) approval of the Phase 1 Investigational New Drug (“IND”) for its radiopharmaceutical therapeutic candidate SKL35501 and imaging agent SKL35502. The therapeutic candidate SKL35501 was in-licensed by SK Biopharmaceuticals from Full-Life in July 2024. The imaging agent SKL35502 utilizes the same NTSR1 target as SKL35501.
About Iterion Therapeutics
Iterion Therapeutics is a clinical-stage oncology company developing first-in-class therapies that target cancers driven by aberrant Wnt/β-catenin signaling. The Company's lead asset, tegavivint, is the first and only small-molecule inhibitor of TBL1, a critical transcriptional regulator required for nuclear β-catenin stability and oncogenic gene expression. Tegavivint has demonstrated clinical tolerability, target engagement, and monotherapy activity in multiple complex solid tumors, including advanced hepatocellular carcinoma, positioning Iterion at the forefront of Wnt/β-catenin drug development.
About Kainova Therapeutics
Kainova Therapeutics is a clinical-stage biopharmaceutical company, headquartered in Montreal, Canada, driving a robust pipeline of breakthrough therapies that precisely modulate G protein-coupled receptors (GPCRs) with a focus on immuno-oncology and inflammation. Kainova Therapeutics' key programs include a unique clinical-stage Treg-depleting anti-CCR8 antibody with differentiated competitive features and a first-in-modality pre-IND stage biased antagonist of PAR2.
About Grove Biopharma
Grove Biopharma is a private biotechnology company developing a new class of therapeutics based on protein-like polymers (PLPs). Through its Bionic Biologics™ platform, Grove integrates advances in synthetic chemistry, precision polymerization, protein and peptide engineering, and medicinal chemistry to create protein-scale architectures capable of targeting disease drivers that have historically been inaccessible to conventional drug modalities. Grove’s PLPs combine key attributes of antibodies with the ability to enter cells and engage intracellular protein–protein interactions. The company’s platform is modular and can be rapidly engineered to enable heterobifunctional designs that support proximity-driven chemistry, including targeted protein degradation. The company is based in Chicago and is part of the city’s emerging life sciences ecosystem. For more information, please visit grovebiopharma.com.
About QurAlis
QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers.
About Genhouse Bio
Suzhou Genhouse Bio Co., Ltd. is a clinical-stage biotech company based in China dedicated to the discovery and development of innovative therapies for cancer. The company leverages its combination of research platforms to advance a pipeline of differentiated drug candidates for global markets.
About ABM Therapeutics
ABM Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for the treatment of cancer, with a particular emphasis on blood–brain barrier penetration and brain metastases. ABM’s pipeline includes multiple programs at various stages of discovery and development, many of which are designed to address significant unmet medical needs in cancers affecting the brain.
About Full-Life Technologies
Full-Life Technologies ("Full-Life") is a fully-integrated clinical-stage global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development.